Cybrexa Therapeutics to Present Virtually at H.C. Wainwright 23rd Annual Global Investment Conference

New Haven, Connecticut, UNITED STATES

NEW HAVEN, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, announced today that management is scheduled to deliver a virtual presentation at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on demand throughout the conference from September 13-15.

About Cybrexa
Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex™ platform. The Company’s lead candidate, CBX-12, an alphalex™-exatecan conjugate, has entered a Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors. Cybrexa also has other preclinical toxin conjugate programs as well as synthetic lethality programs. Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies. For more information about Cybrexa, please visit


Cybrexa Therapeutics
Lisa Rehm

Westwicke, an ICR Company
Investor Relations
Stephanie Carrington
Tel: 646-277-1282

Media Relations
Mark Corbae
Tel: 203-682-8288